Day: October 25, 2021

Ceridian recognition driven by its Ability to Execute and Completeness of Vision TORONTO and MINNEAPOLIS, Oct. 25, 2021 (GLOBE NEWSWIRE) — Ceridian (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, announced it has been named a Leader in the 2021 Gartner Magic Quadrant for Cloud HCM Suites for 1,000+ Employee Enterprises1. Ceridian was recognized for the second consecutive year, driven by Ceridian’s Ability to Execute and Completeness of Vision. “We believe this recognition is a reflection of our ability to continuously deliver innovation through our Dayforce platform, and a validation of our leadership in the global HCM market,” said Joe Korngiebel, Chief Product and Technology Officer, Ceridian. Dayforce is a single HCM platform for the new world of work, one that delivers compliance, workforce...

LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. During the fireside chat, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company’s corporate strategy while highlighting its precision medicine approach, clinical stage vaccine programs in neurodegenerative diseases, and data from the Lauriet Phase 2 trial evaluating semorinemab in mild-to-moderate Alzheimer’s disease. The fireside chat will be available on-demand for attendees during the virtual conference beginning...

Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meeting NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a written interim response from the Office of New Drugs (“OND”) of the U.S. Food and Drug Administration (“FDA”). The letter indicated that the OND needs additional input from an Advisory Committee in order to reach a decision on the Formal Dispute Resolution Request (“FDRR”), the details of which have previously been disclosed. Accordingly, the FDA will convene an Advisory Committee meeting and seek advice from the Anesthetic and Analgesic Drug Products Advisory Committee...

TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQX:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce that it has invested US$400,000 to acquire 1,600,000 common shares of Liquid Marketplace Inc. (“Liquid Marketplace”). With this recent investment, the Company now holds a total of 3,100,000 common shares in Liquid Marketplace at a total cost of US$550,000. Liquid Marketplace is a private company that tokenizes collectible trading cards and unlocks the potential for co-ownership to its users. Liquid Marketplace has created a secondary marketplace where users can trade their ownership amongst each other with instant settlement on trades. “We are thrilled...

-Series II Preferred Shares continue to accrue a 5% annual dividend, payable in shares upon conversion, until April 24, 2022- TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) — Red White & Bloom Brands Inc. (CSE: RWB and OTCQX: RWBYF) (“RWB” or the “Company”), a multi-state cannabis operator and house of premium brands, today announced that certain Company shareholders, representing over 50 million RWB Series II Preferred Shares (the “Preferred Shares”) (together, the “Locked-up Shareholders”), have agreed to a non-conversion lock-up period for their Preferred Shares for a term that expires on April 24th, 2022; the date at which the Preferred Shares are slated for automatic conversion into common shares of the Company. The Agreement shall provide for the Locked-up Shareholders to maintain their current rights as Preferred Share shareholders,...

Highlights:Record net sales of $348.4 million, up 16% as compared to $300.6 million in Q3 2020. Diluted earnings per share (“EPS”) of $1.04, compared to $1.06 in Q3 2020. Adjusted diluted EPS* of $1.18 compared to $1.14 in Q3 2020. Completed acquisition of Dayton Parts, accelerating Dorman’s heavy-duty growth strategy.COLMAR, Pa., Oct. 25, 2021 (GLOBE NEWSWIRE) — Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ:DORM), a leading supplier in the automotive aftermarket industry, today announced its financial results for the third quarter ended September 25, 2021. Third Quarter Financial ResultsDorman reported quarterly net sales in the third quarter of 2021 of $348.4 million, up 16% as compared to net sales of $300.6 million in the third quarter of 2020. The strong net sales performance in the quarter reflected robust...

New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24 weeks Additional PRISM3 microbiome data show CP101 engraftment leads to an increase in intestinal microbiome diversity and sustained clinical cureSOMERVILLE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the presentation of clinical data supporting CP101 for the prevention of recurrent C. difficile infection (CDI) at the American College of Gastroenterology (ACG) Annual Scientific Meeting being...

Company Goal to Enable Minimally-Invasive, Focal Therapy Procedure to be Performed in an Office Setting or Clinic under Local Anesthetic IRVINE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Clinical Laserthermia Systems AB (publ) (CLS), developer of high precision, image-guided focal laser ablation (FLA) systems, today announced that a new generation of its TRANBERG® Thermal Therapy System is being evaluated for MRI-US, fusion-guided laser ablation for the minimally-invasive, targeted focal therapy of prostate tumors. Nearly 200,000 new prostate cancer cases are diagnosed each year in the US with over 1 million biopsies being performed. CLS’s goal is to enable high precision, focal laser ablation of prostate cancer tumors to be performed under local anesthetic in an office setting or clinic as well as hospitals. In June 2021, CLS announced...

GREENWICH, Conn. , Oct. 25, 2021 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading provider of freight transportation services, has been named one of the transportation industry’s top companies for women to work for by the Women in Trucking Association (WIT). WIT is a non-profit organization that works to encourage the employment of women in trucking and minimize the obstacles they face. XPO was selected for its commitment to competitive pay and benefits for women, as well as its gender diversity, work-life accommodations, training and professional development. Josephine Berisha, chief human resources officer for XPO Logistics, said, “This award means a great deal to us, because it reflects our focus on the recruitment and advancement of women in a traditionally male-oriented industry. We’ll continue to open doors...

Company Goal to Enable Minimally-Invasive, Focal Therapy Procedure to be Performed in an Office Setting or Clinic under Local Anesthetic LUND, Sweden, Oct. 25, 2021 (GLOBE NEWSWIRE) — Clinical Laserthermia Systems AB (publ) (CLS), developer of high precision, image-guided focal laser ablation (FLA) systems, today announced that a new generation of its TRANBERG® Thermal Therapy System is being evaluated for MRI-US, fusion-guided laser ablation for the minimally-invasive, targeted focal therapy of prostate tumors. Nearly 200,000 new prostate cancer cases are diagnosed each year in the US with over 1 million biopsies being performed. CLS’s goal is to enable high precision, focal laser ablation of prostate cancer tumors to be performed under local anesthetic in an office setting or clinic as well as hospitals. In June 2021, CLS announced...